name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
A1020S	g.G3058T	p.A1020S			24620	S	S	MISSENSE	126	126	147						118	T=8	8	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A1074V	g.C3221T	p.A1074V			3486	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		86	T=40	40	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A1087S	g.G3259T	p.A1087S			24821	S	S	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A1298V	g.C3893T	p.A1298V			4158	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		86	T=40	40	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A1473A	g.T4419C	p.A1473A			4684	ORF1ab	ORF1a	SILENT	123	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		61	C=62	62	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A2584A	g.G7752T	p.A2584A			8017	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		123	T=3	3	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A2944A	g.T8832C	p.A2944A			9097	ORF1ab	ORF1a	SILENT	126	126	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A35A	g.G105T	p.A35A			28378	N	N	SILENT	125	126	147						62	T=63	63	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A3958A	g.T11874C	p.A3958A			12139	ORF1ab	ORF1a	SILENT	126	126	147			nsp8	produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A4016T	g.G12046A	p.A4016T			12311	ORF1ab	ORF1a	MISSENSE	4	4	147			nsp8	produced by both pp1a and pp1ab		3	A=1	1	A	G						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
A4247A	g.T12741C	p.A4247A			13006	ORF1ab	ORF1a	SILENT	126	126	147			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A474S	g.G1420T	p.A474S			1685	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp2	produced by both pp1a and pp1ab		61	T=65	65	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A4792S	g.G14374T	p.A4792S			14638	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A5713A	g.C17139T	p.A5713A			17403	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A6544V	g.C19631T	p.A6544V			19895	ORF1ab	ORF1b	MISSENSE	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A6802A	g.G20406A	p.A6802A			20670	ORF1ab	ORF1b	SILENT	126	126	147			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		123	A=3	3	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A688V	g.C2063T	p.A688V			23625	S	S	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A783S	g.G2347T	p.A783S			23909	S	S	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A783V	g.C2348T	p.A783V			23910	S	S	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A85S	g.G253T	p.A85S			26775	M	M	MISSENSE	125	126	147						123	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A903T	g.G2707A	p.A903T			2972	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
A968V	g.C2903T	p.A968V			3168	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
C5089F	g.G15266T	p.C5089F			15530	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		124	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D1259Y	g.G3775T	p.D1259Y			25337	S	S	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D1273D	g.C3819T	p.D1273D			4084	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		120	T=6	6	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D128D	g.C384T	p.D128D			28657	N	N	SILENT	7	7	147						0	T=7	7	T	C						False	BB.2, B.1.621.1	BB.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D160D	g.C480T	p.D160D			27002	M	M	SILENT	122	126	147						119	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D1639D	g.T4917C	p.D1639D			5182	ORF1ab	ORF1a	SILENT	125	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		113	C=12	12	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D1897A	g.A5690C	p.D1897A			5955	ORF1ab	ORF1a	MISSENSE	3	3	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		2	C=1	1	C	A						False	BB.2	BB.2=False	de_escalated	30-Aug-2021		
D198G	g.A593G	p.D198G			22155	S	S	MISSENSE	118	126	147						100	G=18	18	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D222Y	g.G664T	p.D222Y			26056	ORF3a	ORF3a	MISSENSE	125	126	147						121	T=4	4	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D238D	g.T714C	p.D238D			26106	ORF3a	ORF3a	SILENT	125	126	147						122	C=3	3	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D2525D	g.C7575T	p.D2525D			7840	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D4200D	g.T12600C	p.D4200D			12865	ORF1ab	ORF1a	SILENT	126	126	147			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D5528D	g.C16584T	p.D5528D			16848	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		123	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D6104D	g.C18312T	p.D6104D			18576	ORF1ab	ORF1b	SILENT	4	4	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		3	T=1	1	T	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	133	133	147						0	G=133	133	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'Q677H'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	133	133	147						0	G=133	133	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'E484K', 'N501Y'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'Q677H'	"Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees."	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	convalescent plasma escape	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N', 'N501Y'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	151	294	147						0	G=151	151	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'Q677H'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'E484K', 'N501Y'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'E484K', 'N501Y'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	transmissibility	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'L452R'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K', 'N501Y'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'E484K', 'N501Y'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccine neutralization efficacy	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'L452R'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L452R'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	126	126	147						0	G=126	126	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T1027I'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	133	133	147						0	G=133	133	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	147	147	147						0	G=147	147	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
D61L	g.GAT181_183CTC	p.D61L			27382	ORF6	ORF6		126	126	147						125	CTC=1	1	CTC	GAT						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D644D	g.C1932T	p.D644D			2197	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
D6724D	g.C20172T	p.D6724D			20436	ORF1ab	ORF1b	SILENT	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
E1724D	g.G5172T	p.E1724D			5437	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417N', 'N501Y'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'N501Y'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'K417N', 'N501Y'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'K417N', 'N501Y'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'N501Y', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'K417N'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'K417N', 'N501Y'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	'R346K'	In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	'L452R'	This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'N501Y', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'N501Y', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'K417N', 'N501Y'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'N501Y'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'K417N'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'N501Y', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'K417N', 'N501Y'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'K417N', 'N501Y'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'N501Y'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'K417N', 'N501Y'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	123	126	147						3	A=120	120	A	G	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'K417N', 'N501Y'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	144	147	147						3	A=141	141	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
E5585D	g.G16755T	p.E5585D			17019	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		83	T=43	43	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
E583D	g.G1749T	p.E583D			23311	S	S	MISSENSE	14	14	147						0	T=14	14	T	G						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
E640E	g.G1920A	p.E640E			2185	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
F23F	g.C69T	p.F23F			26313	E	E	SILENT	125	126	147						124	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
F28L	g.C84A	p.F28L			26606	M	M	MISSENSE	126	126	147						125	A=1	1	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
F3156F	g.C9468T	p.F3156F			9733	ORF1ab	ORF1a	SILENT	4	4	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		3	T=1	1	T	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
F63_L77del	g.187_231delTTTGCTTTTGCTTGTCCTGACGGCGTAAAACACGTCTATCAGTTA	p.F63_L77del			27578	ORF7a	ORF7a		125	126	147						124	AA=1	1	AA	AATTTGCTTTTGCTTGTCCTGACGGCGTAAAACACGTCTATCAGTTA						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
F6628F	g.C19884T	p.F6628F			20148	ORF1ab	ORF1b	SILENT	145	147	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		0	T=145	145	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
F87F	g.C261T	p.F87F			27654	ORF7a	ORF7a	SILENT	125	126	147						122	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	147	147	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=147	147	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
F9F	g.C27T	p.F9F			27782	ORF7b	ORF7b	SILENT	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G202G	g.C606A	p.G202G			27128	M	M	SILENT	122	126	147						121	A=1	1	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G2959S	g.G8875A	p.G2959S			9140	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		123	A=3	3	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G5233G	g.C15699T	p.G5233G			15963	ORF1ab	ORF1b	SILENT	3	3	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=3	3	T	C						False	BB.2	BB.2=True	de_escalated	30-Aug-2021		
G6114G	g.C18342T	p.G6114G			18606	ORF1ab	ORF1b	SILENT	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G618G	g.C1854T	p.G618G			2119	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G6406V	g.G19217T	p.G6406V			19481	ORF1ab	ORF1b	MISSENSE	120	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		119	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G6430G	g.C19290T	p.G6430G			19554	ORF1ab	ORF1b	SILENT	117	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		116	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
G66fs	g.197_201delGTTCT	p.G66fs			28089	ORF8	ORF8		4	4	147			(ORF8|GU280_gp09|1|1.00)			0	GA=3	3	GA	GGTTCTA						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
G894S	g.G2680A	p.G894S			2945	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
H300Y	g.C898T	p.H300Y			29171	N	N	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I20M	g.C60G	p.I20M			25452	ORF3a	ORF3a	MISSENSE	126	126	147						83	G=43	43	G	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I3463I	g.T10389C	p.I3463I			10654	ORF1ab	ORF1a	SILENT	126	126	147			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I4429I	g.C13287T	p.I4429I			13551	ORF1ab	ORF1b	SILENT	125	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		123	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I47T	g.T140C	p.I47T			28033	ORF8	ORF8	MISSENSE	126	126	147						124	C=2	2	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I624I	g.T1872C	p.I624I			23434	S	S	SILENT	126	126	147						124	C=2	2	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
I6257I	g.T18771C	p.I6257I			19035	ORF1ab	ORF1b	SILENT	147	147	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		6	C=141	141	C	T						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
K117N	g.A351C	p.K117N			27744	ORF7a	ORF7a	MISSENSE	126	126	147						86	C=40	40	C	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K1230K	g.G3690A	p.K1230K			3955	ORF1ab	ORF1a	SILENT	125	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		85	A=40	40	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K141_F143del	g.421_429delAAGTCATTT	p.K141_F143del			685	ORF1ab	ORF1a		126	126	147			leader protein	nsp1, produced by both pp1a and pp1ab		125	AG=1	1	AG	AAAGTCATTTG						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K235R	g.A704G	p.K235R			26096	ORF3a	ORF3a	MISSENSE	125	126	147						124	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K38E	g.A112G	p.K38E			27313	ORF6	ORF6	MISSENSE	126	126	147						125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K', 'N501Y'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K', 'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'E484K', 'N501Y'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'E484K', 'N501Y'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'E484K', 'N501Y', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K', 'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'E484K'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'E484K', 'N501Y'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.1 fold	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'E484K', 'N501Y', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'E484K', 'N501Y', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'E484K', 'N501Y'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'E484K'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'E484K', 'N501Y', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'E484K', 'N501Y'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'E484K', 'N501Y'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'E484K', 'N501Y'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'E484K', 'N501Y'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K417N	g.G1251T	p.K417N			22813	S	S	MISSENSE	126	126	147						61	T=65	65	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
K5784R	g.A17351G	p.K5784R			17615	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L106F	g.C316T	p.L106F			25708	ORF3a	ORF3a	MISSENSE	126	126	147						120	T=6	6	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L112L	g.T336C	p.L112L			27729	ORF7a	ORF7a	SILENT	125	126	147						124	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L1356L	g.C4066T	p.L1356L			4331	ORF1ab	ORF1a	SILENT	124	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		114	T=10	10	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L1627L	g.C4879T	p.L1627L			5144	ORF1ab	ORF1a	SILENT	14	14	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=14	14	T	C						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
L1643L	g.C4927T	p.L1643L			5192	ORF1ab	ORF1a	SILENT	146	147	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		124	T=22	22	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621.2=True, B.1.621=False, B.1.621.1=True	de_escalated	30-Aug-2021		
L1797L	g.C5389T	p.L1797L			5654	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L2084L	g.A6252G	p.L2084L			6517	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L2333F	g.C6997T	p.L2333F			7262	ORF1ab	ORF1a	MISSENSE	4	4	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		3	T=1	1	T	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
L291L	g.C871T	p.L291L			29144	N	N	SILENT	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L3505L	g.C10513T	p.L3505L			10778	ORF1ab	ORF1a	SILENT	124	126	147			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		123	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L3585L	g.C10755T	p.L3585L			11020	ORF1ab	ORF1a	SILENT	14	14	147			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		0	T=14	14	T	C						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
L3602F	g.G10806T	p.L3602F			11071	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	139	140	147	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		136	T=3	3	T	G						False	B.1.621, B.1.621.2	B.1.621.2=False, B.1.621=False	de_escalated	30-Aug-2021		
L3879L	g.C11637T	p.L3879L			11902	ORF1ab	ORF1a	SILENT	126	126	147			nsp7	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L4070L	g.C12208T	p.L4070L			12473	ORF1ab	ORF1a	SILENT	126	126	147			nsp8	produced by both pp1a and pp1ab		123	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~1.7-fold increase in binding affinity vs wild type.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	T cell evasion	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf		L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera  donor plasma (linear epitope NYNYLYRLF 448,456).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	antibody epitope effects	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	antibody epitope effects	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	antibody epitope effects	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape mechanism for certain RBD-targeting mAbs.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Observed ~2x decrease on average in 16 health workers' convalescent sera.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	convalescent plasma escape	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.32 fold	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation. Cligavimab lost ~4x binding against this isolated mutation. Regdanvimab lost ~4x binding against this isolated mutation.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	pharmaceutical effectiveness	McCallum et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1		Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of L452R in the epitopes recognized by this mAb. Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	trafficking	Deng et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1		We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,  with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. [listed as L454R in Figure, but L452R in text, also text  suggests not statistucally significant, but error bars say otherwise in Figure 4]	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	'E484K'	This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	transmissibility	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.  [In combination with E484Q caused a lower 3-fold increase]	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. L452R conferred about a two-fold reduction in neutralisation by vaccine sera, but was not statistically significant with this sample size.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2	'N501Y'	The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	vaccine neutralization efficacy	Wilhelm et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	'D614G'	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L452R	g.T1355G	p.L452R			22917	S	S	MISSENSE	122	126	147						121	G=1	1	G	T	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L4862L	g.C14584T	p.L4862L			14848	ORF1ab	ORF1b	SILENT	125	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		115	T=10	10	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
L4I	g.C10A	p.L4I			27211	ORF6	ORF6	MISSENSE	4	4	147						3	A=1	1	A	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
L6205L	g.C18613T	p.L6205L			18877	ORF1ab	ORF1b	SILENT	146	147	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		0	T=146	146	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
L730L	g.C2190T	p.L730L			2455	ORF1ab	ORF1a	SILENT	125	126	147			nsp2	produced by both pp1a and pp1ab		124	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
M109I	g.G327T	p.M109I			26849	M	M	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
M1229I	g.G3687T	p.M1229I			25249	S	S	MISSENSE	126	126	147						123	T=3	3	T	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage, was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slight decrease in infection rate amongst the cells, suggesting that this  variant does not contributing to human cell entry fitness.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
M2036I	g.G6108T	p.M2036I			6373	ORF1ab	ORF1a	MISSENSE	3	3	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1	T=2	2	T	G						False	BB.2	BB.2=False	de_escalated	30-Aug-2021		
N1074N	g.C3222T	p.N1074N			24784	S	S	SILENT	4	4	147						1	T=3	3	T	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
N126N	g.C378T	p.N126N			643	ORF1ab	ORF1a	SILENT	126	126	147			leader protein	nsp1, produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
N188N	g.C564T	p.N188N			829	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
N2147D	g.A6439G	p.N2147D			6704	ORF1ab	ORF1a	MISSENSE	4	4	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	G=4	4	G	A						False	B.1.621.1	B.1.621.1=True	de_escalated	30-Aug-2021		
N4560N	g.C13680T	p.N4560N			13944	ORF1ab	ORF1b	SILENT	14	14	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		9	T=5	5	T	C						False	B.1.621.2	B.1.621.2=False	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417N', 'E484K'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'D614G', 'Q677H'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'K417N', 'E484K'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'K417N', 'E484K'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'E484K', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'D614G', 'Q677H'	"Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees."	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'K417N', 'E484K'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	147	294	147						1	T=146	146	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'D614G', 'Q677H'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'E484K', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'E484K', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'K417N', 'E484K'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'E484K'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2	'L452R'	The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'E484K', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'K417N', 'E484K'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'K417N', 'E484K'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'E484K'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'K417N', 'E484K'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	122	126	147						1	T=121	121	T	A	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'K417N', 'E484K'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
N501Y	g.A1501T	p.N501Y			23063	S	S	MISSENSE	143	147	147						1	T=142	142	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
NK2147DR	g.AACAA6439_6443GACAG	p.NK2147DR			6704	ORF1ab	ORF1a		3	3	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	GACAG=3	3	GACAG	AACAA						False	BB.2	BB.2=True	de_escalated	30-Aug-2021		
P2376P	g.G7128T	p.P2376P			7393	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P38S	g.C112T	p.P38S			28005	ORF8	ORF8	MISSENSE	143	147	147	caution	neighbour_linked,single_src				0	T=143	143	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P4058P	g.C12174T	p.P4058P			12439	ORF1ab	ORF1a	SILENT	126	126	147			nsp8	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P463P	g.T1389C	p.P463P			22951	S	S	SILENT	123	126	147						122	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P4715L	g.C14144T	p.P4715L			14408	ORF1ab	ORF1b	MISSENSE	147	147	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	T=147	147	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P5347P	g.A16041G	p.P5347P			16305	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P5371P	g.G16113A	p.P5371P			16377	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P5496H	g.C16487A	p.P5496H			16751	ORF1ab	ORF1b	MISSENSE	125	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		61	A=64	64	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P5743S	g.C17227T	p.P5743S			17491	ORF1ab	ORF1b	MISSENSE	145	147	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		0	T=145	145	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P5815S	g.C17443T	p.P5815S			17707	ORF1ab	ORF1b	MISSENSE	147	147	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=22	22	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621.2=True, B.1.621=False, B.1.621.1=True	de_escalated	30-Aug-2021		
P5853L	g.C17558T	p.P5853L			17822	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P6065T	g.C18193A	p.P6065T			18457	ORF1ab	ORF1b	MISSENSE	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		125	A=1	1	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P6376S	g.C19126T	p.P6376S			19390	ORF1ab	ORF1b	MISSENSE	121	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		120	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P681H	g.C2042A	p.P681H			23604	S	S	MISSENSE	147	147	147						0	A=147	147	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
P84S	g.C250T	p.P84S			27643	ORF7a	ORF7a	MISSENSE	125	126	147						124	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q1332Q	g.G3996A	p.Q1332Q			4261	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q1792Q	g.A5376G	p.Q1792Q			5641	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q1800Q	g.G5400A	p.Q1800Q			5665	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		124	A=2	2	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q3729R	g.A11186G	p.Q3729R			11451	ORF1ab	ORF1a	MISSENSE	147	147	147			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		0	G=147	147	G	A						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
Q384H	g.G1152T	p.Q384H			29425	N	N	MISSENSE	126	126	147	mask	ambiguous,homoplasic,single_src				124	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q57H	g.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	146	147	147						1	T=21, TAT=1	21,1	T,TAT	G						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621.2=True, B.1.621=False, B.1.621.1=True	de_escalated	30-Aug-2021		
Q5872Q	g.A17616G	p.Q5872Q			17880	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		111	G=15	15	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q677H	g.G2031C	p.Q677H			23593	S	S	MISSENSE	126	126	147						125	C=1	1	C	G	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'D614G'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70% drop in IC50 (i.e. increased affinity).	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q677H	g.G2031C	p.Q677H			23593	S	S	MISSENSE	126	126	147						125	C=1	1	C	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'D614G'	"Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees."	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q677H	g.G2031C	p.Q677H			23593	S	S	MISSENSE	126	126	147						125	C=1	1	C	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'N501Y', 'D614G'	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q94H	g.A282C	p.Q94H			27675	ORF7a	ORF7a	MISSENSE	14	14	147						0	C=14	14	C	A						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
Q94K	g.C280A	p.Q94K			27673	ORF7a	ORF7a	MISSENSE	126	126	147						125	A=1	1	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Q970K	g.C2908A	p.Q970K			3173	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	A=1	1	A	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
QS57HI	g.GAG171_173TAT	p.QS57HI			25563	ORF3a	ORF3a		125	126	147						1	TAG=123	123	TAG	GAG						False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
R146H	g.G437A	p.R146H			26959	M	M	MISSENSE	14	14	147						0	A=14	14	A	G						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
R200S	g.G600T	p.R200S			27122	M	M	MISSENSE	122	126	147						121	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
R346K	g.CAG1035_1037AAA	p.R346K			22597	S	S		14	14	147						0	AAA=14	14	AAA	CAG	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
R346K	g.CAG1035_1037AAA	p.R346K			22597	S	S		14	14	147						0	AAA=14	14	AAA	CAG	monoclonal antibody serial passage escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	'E484K'	In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
R346K	g.CAG1035_1037AAA	p.R346K			22597	S	S		14	14	147						0	AAA=14	14	AAA	CAG	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
R346K	g.G1037A	p.R346K			22599	S	S	MISSENSE	133	133	147						0	A=133	133	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
R346K	g.G1037A	p.R346K			22599	S	S	MISSENSE	133	133	147						0	A=133	133	A	G	monoclonal antibody serial passage escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	'E484K'	In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
R346K	g.G1037A	p.R346K			22599	S	S	MISSENSE	133	133	147						0	A=133	133	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
R398R	g.T1194C	p.R398R			1459	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
R402R	g.C1206T	p.R402R			1471	ORF1ab	ORF1a	SILENT	126	126	147			nsp2	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
R52I	g.G155T	p.R52I			28048	ORF8	ORF8	MISSENSE	4	4	147						1	T=3	3	T	G						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
R6088C	g.C18262T	p.R6088C			18526	ORF1ab	ORF1b	MISSENSE	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		123	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
R78C	g.C232T	p.R78C			27625	ORF7a	ORF7a	MISSENSE	124	126	147						123	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S1515S	g.C4545T	p.S1515S			4810	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S1924S	g.C5772T	p.S1924S			6037	ORF1ab	ORF1a	SILENT	147	147	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=147	147	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
S2433S	g.C7299T	p.S2433S			7564	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S2500F	g.C7499T	p.S2500F			7764	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S327L	g.C980T	p.S327L			29253	N	N	MISSENSE	126	126	147						122	T=4	4	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S3885F	g.C11654T	p.S3885F			11919	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp7	produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S40L	g.C119T	p.S40L			25511	ORF3a	ORF3a	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S413I	g.G1238T	p.S413I			29511	N	N	MISSENSE	126	126	147						118	T=8	8	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S4264S	g.A12792T	p.S4264S			13057	ORF1ab	ORF1a	SILENT	147	147	147			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		0	T=147	147	T	A						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	ACE2 receptor binding affinity	Chakraborty (2021)	https://doi.org/10.1016/j.bbrc.2021.01.035		Using molecular dynamic simulation, the mildly (~1kcal/mol) enhanced binding energy of this variant is primarily  contributed by Tyr505 (−4.98 kcal/mol) which is now involved in a strong hydrogen bonding network with Arg393.  Another important energetic contribution comes from the altered orientation of Tyr41 which is now involved with  two hydrogen-bonding interactions with Asp355 and Thr500. 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Minor variant selected in late rounds of an in vitro evolution experiment for ACE2 binding. Shown to increase the thermostability but decrease the association rate constant of the RBD to ACE2	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	convalescent plasma escape	Alenquer et al. (2021)	http://biorxiv.org/cgi/content/short/2021.04.22.441007		S494P frequently engages in interactions with antibodies but not with ACE2. It reduces antibody  neutralization of all 16 convalescent sera tested, averaging WT ratio of 0.41+-0.08 (less dramatic than E484K).  This amino acid emerges as an additional hotspot for immune evasion and a target for therapies, vaccines and diagnostics. It has emerged independently in multiple lineages.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	convalescent plasma escape	Greaney et al. (2021)	https://doi.org/10.1016/j.chom.2021.02.003		In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  S484P shows a slightly resistent profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution)	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab. 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S494P	g.T1480C	p.S494P			23042	S	S	MISSENSE	123	126	147						122	C=1	1	C	T	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation. Regdanvimab lost ~32x binding against this isolated mutation.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S546L	g.C1637T	p.S546L			1902	ORF1ab	ORF1a	MISSENSE	14	14	147			nsp2	produced by both pp1a and pp1ab		13	T=1	1	T	C						False	B.1.621.2	B.1.621.2=False	de_escalated	30-Aug-2021		
S5809L	g.C17426T	p.S5809L			17690	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S60S	g.C180T	p.S60S			21742	S	S	SILENT	121	126	147						120	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S6549F	g.C19646T	p.S6549F			19910	ORF1ab	ORF1b	MISSENSE	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		120	T=6	6	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S6713L	g.C20138T	p.S6713L			20402	ORF1ab	ORF1b	MISSENSE	133	133	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		123	T=10	10	T	C						False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=False, B.1.621.1=True	de_escalated	30-Aug-2021		
S6725I	g.G20174T	p.S6725I			20438	ORF1ab	ORF1b	MISSENSE	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S67F	g.C200T	p.S67F			28089	ORF8	ORF8	MISSENSE	4	4	147			(ORF8|GU280_gp09|1|1.00)			0	GGTTTTA=1	1	GGTTTTA	GGTTCTA						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
S67F	g.C200T	p.S67F			28093	ORF8	ORF8	MISSENSE	133	143	147						0	T=133	133	T	C						False	B.1.621, BB.2, B.1.621.2	BB.2=True, B.1.621=True, B.1.621.2=True	de_escalated	30-Aug-2021		
S6831I	g.G20492T	p.S6831I			20756	ORF1ab	ORF1b	MISSENSE	125	126	147			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		123	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S7059F	g.C21176T	p.S7059F			21440	ORF1ab	ORF1b	MISSENSE	124	126	147			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		122	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S723F	g.C2168T	p.S723F			2433	ORF1ab	ORF1a	MISSENSE	125	126	147			nsp2	produced by both pp1a and pp1ab		124	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
S939F	g.C2816T	p.S939F			24378	S	S	MISSENSE	3	3	147						0	T=3	3	T	C						False	BB.2	BB.2=True	de_escalated	30-Aug-2021		
S966F	g.C2897T	p.S966F			3162	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1027I	g.C3080T	p.T1027I			24642	S	S	MISSENSE	126	126	147						125	T=1	1	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1027I	g.C3080T	p.T1027I			24642	S	S	MISSENSE	126	126	147						125	T=1	1	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1027I	g.C3080T	p.T1027I			24642	S	S	MISSENSE	126	126	147						125	T=1	1	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1027I	g.C3080T	p.T1027I			24642	S	S	MISSENSE	126	126	147						125	T=1	1	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1055A	g.A3163G	p.T1055A			3428	ORF1ab	ORF1a	MISSENSE	145	147	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	G=145	145	G	A						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T115T	g.T345A	p.T115T			28618	N	N	SILENT	126	126	147						120	A=6	6	A	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1171A	g.A3511G	p.T1171A			3776	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	G=1	1	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T11K	g.C32A	p.T11K			27925	ORF8	ORF8	MISSENSE	147	147	147						0	A=147	147	A	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T1269A	g.A3805G	p.T1269A			4070	ORF1ab	ORF1a	MISSENSE	4	4	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1	G=3	3	G	A						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
T12I	g.C35T	p.T12I			25427	ORF3a	ORF3a	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T14I	g.C41T	p.T14I			25433	ORF3a	ORF3a	MISSENSE	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T1538I	g.C4613T	p.T1538I			4878	ORF1ab	ORF1a	MISSENSE	145	147	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=145	145	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T205I	g.C614T	p.T205I			28887	N	N	MISSENSE	145	147	147						0	T=145	145	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T2069T	g.C6207T	p.T2069T			6472	ORF1ab	ORF1a	SILENT	4	4	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		3	T=1	1	T	C						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
T2300T	g.C6900T	p.T2300T			7165	ORF1ab	ORF1a	SILENT	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T274T	g.T822A	p.T274T			22384	S	S	SILENT	5	7	147						0	A=5	5	A	T						False	BB.2, B.1.621.1	BB.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T2952I	g.C8855T	p.T2952I			9120	ORF1ab	ORF1a	MISSENSE	7	7	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	T=7	7	T	C						False	BB.2, B.1.621.1	BB.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T3150I	g.C9449T	p.T3150I			9714	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T3255I	g.C9764T	p.T3255I			10029	ORF1ab	ORF1a	MISSENSE	147	147	147			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	T=147	147	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T379I	g.C1136T	p.T379I			29409	N	N	MISSENSE	3	3	147						0	T=3	3	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BB.2	BB.2=True	de_escalated	30-Aug-2021		
T391I	g.C1172T	p.T391I			29445	N	N	MISSENSE	14	14	147						0	T=14	14	T	C						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
T4159I	g.C12476T	p.T4159I			12741	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T4736I	g.C14207T	p.T4736I			14471	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T4786M	g.C14357T	p.T4786M			14621	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T478K	g.C1433A	p.T478K			22995	S	S	MISSENSE	123	126	147						122	A=1	1	A	C	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab. 	False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T5195I	g.C15584T	p.T5195I			15848	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T54T	g.C162T	p.T54T			28435	N	N	SILENT	126	126	147						125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T5507T	g.T16521C	p.T5507T			16785	ORF1ab	ORF1b	SILENT	4	4	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1	C=3	3	C	T						False	B.1.621.1	B.1.621.1=False	de_escalated	30-Aug-2021		
T572I	g.C1715T	p.T572I			23277	S	S	MISSENSE	126	126	147						124	T=2	2	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T6022I	g.C18065T	p.T6022I			18329	ORF1ab	ORF1b	MISSENSE	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T812I	g.C2435T	p.T812I			2700	ORF1ab	ORF1a	MISSENSE	14	14	147			nsp2	produced by both pp1a and pp1ab		0	T=14	14	T	C						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
T882I	g.C2645T	p.T882I			2910	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	123	133	147						0	T=123	123	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	123	133	147						0	T=123	123	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
T95I	g.C284T	p.T95I			21846	S	S	MISSENSE	123	133	147						0	T=123	123	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
V1176V	g.T3528C	p.V1176V			25090	S	S	SILENT	126	126	147						125	C=1	1	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V1264L	g.G3790T	p.V1264L			25352	S	S	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V2066V	g.G6198T	p.V2066V			6463	ORF1ab	ORF1a	SILENT	124	126	147			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		122	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V256_I263del	g.766_789delGTTAATCCAGTAATGGAACCAATT	p.V256_I263del			26155	ORF3a	ORF3a		122	126	147			(ORF3a|GU280_gp03|1|1.00)			0	GTTATCCAGTAATGGAACCAAT=112	112	GTTATCCAGTAATGGAACCAAT	GTTGTTAATCCAGTAATGGAACCAAT						False	B.1.621	B.1.621=True	de_escalated	30-Aug-2021		
V256fs	g.766_769delGTTA	p.V256fs			26155	ORF3a	ORF3a		122	126	147			(ORF3a|GU280_gp03|1|1.00)			0	GT=10	10	GT	GTTGTTAATCCAGTAATGGAACCAAT						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V256fs	g.766_769delGTTA	p.V256fs			26157	ORF3a	ORF3a		21	21	147			(ORF3a|GU280_gp03|1|1.00)			0	TA=21	21	TA	TGTTAA						False	BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
V259L	g.G775T	p.V259L			26167	ORF3a	ORF3a	MISSENSE	7	7	147						0	T=7	7	T	G						False	BB.2, B.1.621.1	BB.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
V3629V	g.C10887T	p.V3629V			11152	ORF1ab	ORF1a	SILENT	14	14	147			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		0	T=14	14	T	C						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
V3759G	g.T11276G	p.V3759G			11541	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		125	G=1	1	G	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V4147I	g.G12439A	p.V4147I			12704	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		125	A=1	1	A	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V543A	g.T1628C	p.V543A			1893	ORF1ab	ORF1a	MISSENSE	126	126	147			nsp2	produced by both pp1a and pp1ab		124	C=2	2	C	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V5550L	g.G16648T	p.V5550L			16912	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V5672L	g.G17014T	p.V5672L			17278	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		124	T=2	2	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V5819V	g.G17457T	p.V5819V			17721	ORF1ab	ORF1b	SILENT	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V5894L	g.G17680T	p.V5894L			17944	ORF1ab	ORF1b	MISSENSE	126	126	147			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V5954V	g.T17862A	p.V5954V			18126	ORF1ab	ORF1b	SILENT	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		120	A=6	6	A	T						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V6050F	g.G18148T	p.V6050F			18412	ORF1ab	ORF1b	MISSENSE	126	126	147			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		61	T=65	65	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V6770V	g.C20310T	p.V6770V			20574	ORF1ab	ORF1b	SILENT	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		125	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V6772L	g.G20314T	p.V6772L			20578	ORF1ab	ORF1b	MISSENSE	126	126	147			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only		120	T=6	6	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
V84_V86del	g.251_259delTTATGGTTG	p.V84_V86del			513	ORF1ab	ORF1a		126	126	147			leader protein	nsp1, produced by both pp1a and pp1ab		125	AT=1	1	AT	ATGTTATGGTT						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
W45L	g.G134T	p.W45L			28027	ORF8	ORF8	MISSENSE	126	126	147						125	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
W69L	g.G206T	p.W69L			25598	ORF3a	ORF3a	MISSENSE	126	126	147						123	T=3	3	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
Y144_Y145delinsTSN	g.TATT430_433ACTTCTA	p.Y144_Y145delinsTSN			21990	S	S		123	133	147						0	TTACTTCTA=123	123	TTACTTCTA	TTTATT						False	B.1.621, BB.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.1=True	de_escalated	30-Aug-2021		
Y449N	g.T1345A	p.Y449N			22907	S	S	MISSENSE	14	14	147						0	A=14	14	A	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.07 fold	False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
Y4913C	g.A14738G	p.Y4913C			15002	ORF1ab	ORF1b	MISSENSE	126	126	147			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		77	G=49	49	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
g.A-2T	g.A-2T				28272	N	intergenic		147	147	147						1	T=146	146	T	A						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
g.A-31T	g.A-31T				26492	M	intergenic		147	147	147						0	T=147	147	T	A						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
g.A29700G	g.A29700G				29700	intergenic	intergenic		126	126	147						120	G=6	6	G	A						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
g.C-17T	g.C-17T				26228	E	intergenic		125	126	147						124	T=1	1	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
g.C-24T	g.C-24T				26499	M	intergenic		125	126	147						122	T=3	3	T	C						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
g.C-25T	g.C-25T				241	ORF1ab	intergenic		147	147	147						0	T=147	147	T	C						False	B.1.621, BB.2, B.1.621.2, B.1.621.1	BB.2=True, B.1.621=True, B.1.621.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
g.G29736A	g.G29736A				29736	intergenic	intergenic		139	140	147						124	A=15	15	A	G						False	B.1.621, B.1.621.2	B.1.621.2=True, B.1.621=False	de_escalated	30-Aug-2021		
g.G29779T	g.G29779T				29779	intergenic	intergenic		110	126	147						109	T=1	1	T	G						False	B.1.621	B.1.621=False	de_escalated	30-Aug-2021		
g.T-89C	g.T-89C				177	ORF1ab	intergenic		14	14	147						0	C=14	14	C	T						False	B.1.621.2	B.1.621.2=True	de_escalated	30-Aug-2021		
g.T29748C	g.T29748C				29748	intergenic	intergenic		7	7	147						0	C=7	7	C	T						False	BB.2, B.1.621.1	BB.2=True, B.1.621.1=True	de_escalated	30-Aug-2021		
